- ISIN
- US19243B1026
- CUSIP
- 19243B102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 8, 2021
Highlights
- Market Cap
- $149.84M
- Enterprise Value
- $119.47M
- EPS (TTM)
- -$0.24
- Gross Profit (TTM)
- -$129.00K
- EBITDA (TTM)
- -$23.57M
- Year Range
- $0.29 - $3.83
- ROA (TTM)
- -54.17%
- ROE (TTM)
- -65.45%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CGTX Performance Chart
Cognition Therapeutics, Inc. (CGTX) is up 24.4% since the beginning of the year. At $2 per share, CGTX is trading 56.1% below its 52-week high of $4.
Loading charts...
Returns By Period
Cognition Therapeutics, Inc. (CGTX) has returned 24.44% so far this year and 558.82% over the past 12 months.
Cognition Therapeutics, Inc.
- 1D
- 15.86%
- 1M
- 33.33%
- YTD
- 24.44%
- 6M
- 5.66%
- 1Y
- 558.82%
- 3Y*
- -15.15%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CGTX Monthly Returns History
Based on dividend-adjusted daily data since Oct 8, 2021, CGTX's average daily return is +0.10%, while the average monthly return is +3.87%. At this rate, an investment would double in approximately 1.5 years.
Historically, 33% of months were positive and 67% were negative. The best month was Aug 2025 with a return of +314.8%, while the worst month was Sep 2025 at -44.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CGTX closed higher 43% of trading days. The best single day was Aug 4, 2022 with a return of +62.2%, while the worst single day was Jul 29, 2024 at -43.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.26% | 0.00% | -30.32% | 65.90% | -6.35% | 42.37% | 24.44% | ||||||
| 2025 | 3.09% | -37.08% | -7.50% | 1.45% | -44.01% | 29.62% | 89.09% | 314.82% | -44.44% | 32.59% | -2.79% | -22.41% | 92.50% |
| 2024 | 22.70% | -8.81% | -12.08% | 4.95% | 2.09% | -14.87% | -39.76% | -28.86% | -34.13% | 0.75% | -14.85% | 74.45% | -62.09% |
| 2023 | -6.19% | -18.78% | 23.75% | -10.10% | 15.17% | -10.73% | -9.29% | -6.63% | -7.10% | -22.22% | -0.89% | 66.67% | -11.90% |
| 2022 | -30.38% | -30.23% | -10.42% | 0.73% | -5.42% | -19.47% | -10.43% | 8.47% | -7.32% | -6.32% | 97.19% | -40.17% | -66.77% |
| 2021 | -0.49% | -28.21% | -27.19% | -47.98% |
Benchmark Metrics
Cognition Therapeutics, Inc. has an annualized alpha of 8.27%, beta of 1.38, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since October 08, 2021.
- This stock participated in 206.76% of S&P 500 Index downside but only 36.46% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.27%
- Beta
- 1.38
- R²
- 0.04
- Upside Capture
- 36.46%
- Downside Capture
- 206.76%
Return for Risk
Risk / Return Rank
CGTX ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cognition Therapeutics, Inc. (CGTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CGTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.01 | ||
| Sortino ratioReturn per unit of downside risk | +0.93 | ||
| Omega ratioGain probability vs. loss probability | 1.47 | 1.37 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 6.93 | 2.78 | +4.15 |
| Martin ratioReturn relative to average drawdown | 10.88 | 12.44 | -1.56 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cognition Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cognition Therapeutics, Inc. was 98.16%, occurring on May 30, 2025. The portfolio has not yet recovered.
The current Cognition Therapeutics, Inc. drawdown is 87.06%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.16%May 2025 | 3y 6mo | — | 4y 7moNov 2021 - now |
2021 pullback2021 | -6.81%Oct 2021 | 4d | 25d | 29dOct 2021 - Nov 2021 |
Drawdown Indicators
| CGTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.16% | -56.78% | -41.38% |
Max Drawdown (1Y)Largest decline over 1 year | -81.30% | -9.10% | -72.20% |
Max Drawdown (3Y)Largest decline over 3 years | -91.49% | -18.90% | -72.59% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.06% | -1.80% | -85.26% |
Average DrawdownAverage peak-to-trough decline | -84.29% | -10.71% | -73.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.70% | 2.03% | +49.67% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cognition Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cognition Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CGTX in comparison with other companies in the Biotechnology industry. Currently, CGTX has a P/B value of 5.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CGTX
Add Cognition Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CGTX